CrownBio Releases MuBase® 2.0, An Open Access Database of Immuno-Oncology Murine Models
Updates enhance user experience, provide comprehensive characterization data, and add new models
SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has released MuBase 2.0.
MuBase is CrownBio’s proprietary, free-to-access online database featuring the world’s largest collection of validated and characterized murine immuno-oncology models. MuBase collates tumor pathology, genomic characterization, and in vivo pharmacology data for a large selection of immuno-oncology models; syngeneics, GEMM, tumor homografts, and humanized target models.
MuBase 2.0 centers around a large data release including baseline immune profiles and RNAseq on the Company’s exclusive MuPrime® tumor homografts, with 79 models readily available for immuno-oncology studies.
In addition, the platform boasts a redesigned navigation experience and provides a more user-friendly search with simplified data browsing functionality for gene expression. The improvements to MuBase 2.0 make it a powerful everyday tool for early stage in vivo pharmacology and immuno-oncology research.
“To successfully interrogate immuno-oncology preclinical models and advance novel biological agents, a detailed understanding of each model’s genetic and immunological features is paramount,” said Dr. Henry Li, Senior VP of Research and Innovation at Crown Bioscience.
“This ongoing investment in improving our open access databases demonstrates CrownBio’s commitment to providing the most relevant data for the most appropriate in vivo model for each drug discovery program,” said Jean Pierre Wery, CEO of Crown Bioscience.
To learn more about MuBase visit: https://www.crownbio.com/oncology/oncology-databases/mubase .
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
For more information on CrownBio’s commitment to furthering the field drug discovery, visit https://www.crownbio.com
Crown Bioscience Inc.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Erytech Pharma S.A.18.1.2019 07:01 | Pressemeddelelse
ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting
Taconic Biosciences17.1.2019 15:31 | Pressemeddelelse
Taconic Biosciences’ Animals Complete Most Recent Mission to the International Space Station
MPP Global17.1.2019 12:31 | Pressemeddelelse
MPP Global Bridges the Innovation Gap by Centralising Physical and Digital Subscriber Management and Billing in a Single Cloud Platform
ADC Therapeutics SA16.1.2019 07:01 | Pressemeddelelse
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
CGAP15.1.2019 14:10 | Pressemeddelelse
Credit Suisse Partners with CGAP on Digital Finance to Catalyze Delivery of Energy, Water and other Services to Low Income People
TrueCommerce15.1.2019 14:01 | Pressemeddelelse
TrueCommerce Recognized as a Leader in IDC MarketScape for Worldwide Multi-Enterprise Supply Chain Commerce Network
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum